Journal article

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients

MSY Goh, C McCormack, HV Dinh, B Welsh, P Foley, HM Prince

BRITISH JOURNAL OF DERMATOLOGY | BLACKWELL PUBLISHING | Published : 2007

Abstract

BACKGROUND: Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B lymphocytes. There are reports of its efficacy in the treatment of autoimmune diseases, including pemphigus. OBJECTIVES: Prospectively to evaluate the efficacy of rituximab as adjuvant treatment for pemphigus vulgaris (PV). METHODS: Patients with PV were treated with intravenous rituximab (375 mg m(-2)) weekly for 4 weeks in this prospective open-label pilot study. Other concurrent immunosuppression was continued. RESULTS: Of five patients, one achieved complete remission and was able to cease all medication, while two achieved clearance of clinical lesions but continued on systemic therapy. Two p..

View full abstract